This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
For pain sensitive patients with shallow or irregular wounds, wounds with undermining or explored tracts or tunnels, gauze may be used, while foam may be cut easily to fit a patient's wound that has a regular contour and perform better when aggressive granulation formation and wound contraction is the desired goal.
Cows is a chain of ice cream parlours and cheesemongers with nine locations in Canada and one in the United States. It started in 1983 in Prince Edward Island as an ice cream parlour. Today it is known for its 32 varieties of ice cream, cheddar cheese, and cow-themed merchandise. Sales of Cows ice cream spiked in the summer of 2010, after American television hosts Regis and Kelly showed interest in the chain.
Much of the treaty is devoted to fighting organized crime by mandating cooperation in tracing and seizing drug-related assets. Article 5 of the Convention requires its parties to confiscate proceeds from drug offenses. It also requires parties to empower its courts or other competent authorities to order that bank, financial, or commercial records be made available or seized. The Convention further states that a party may not decline to act on this provision on the ground of bank secrecy. Article 6 of the Convention provides a legal basis for extradition in drug-related cases among countries having no other extradition treaties. In addition, the Convention requires the parties to provide mutual legal assistance to one another upon request, for purposes of searches, seizures, service of judicial documents, and so on. In addition, Article 12 of the Convention establishes two categories of controlled illicit drug precursor substances, Table I and Table II. The Commission on Narcotic Drugs has power to decide whether to control a precursor substance, and which Table to place it in. The assessment of the International Narcotics Control Board is binding on the commission, however, as to scientific matters. A two-thirds vote is required to add a substance to a Table.
=== CTS and activity === Work-related factors that increase risk of CTS include vibration (5.4 odds ratio), hand force (4.2), and repetition (2.3). Exposure to wrist extension or flexion at work increases the risk of CTS by 2.0 times. As of 2023, a systematic review of studies looking at the relationship between CTS and computer use has found current studies to be inconclusive and contradictory, due to poor study methods and confounding variables not being accounted for. The international debate regarding the relationship between CTS and repetitive hand use (at work in particular) is ongoing. The Occupational Safety and Health Administration (OSHA) has adopted rules and regulations regarding so-called "cumulative trauma disorders" based concerns regarding potential harm from exposure to repetitive tasks, force, posture, and vibration. A review of available scientific data by the National Institute for Occupational Safety and Health (NIOSH) indicated that job tasks that involve highly repetitive manual acts or specific wrist postures were associated with symptoms of CTS. There was no clear distinction between paresthesia (appropriate) from pain (inappropriate), and causation was not established. The distinction from work-related arm pains that are not carpal tunnel syndrome was unclear. It is proposed that repetitive use of the arm can affect the biomechanics of the upper limb or cause damage to tissues.
== H == Hajos–Parrish–Eder–Sauer–Wiechert reaction Haller–Bauer reaction Haloform reaction Halogen addition reaction Halohydrin formation reaction Hammick reaction Hammond principle or Hammond postulate Hantzsch pyrrole synthesis Hantzsch dihydropyridine synthesis, Hantzsch pyridine synthesis Hantzsch pyridine synthesis, Gattermann–Skita synthesis, Guareschi–Thorpe condensation, Knoevenagel–Fries modification Hantzsch–Collidin synthesis Harries ozonolysis Haworth methylation Haworth synthesis Hay coupling Hayashi rearrangement Heck reaction Hegedus indole synthesis Helferich method Hell–Volhard–Zelinsky halogenation Hemetsberger indole synthesis Hemetsberger–Knittel synthesis Henkel reaction, Raecke process, Henkel process Henry reaction, Kamlet reaction Herz reaction, Herz compounds Herzig–Meyer alkimide group determination Heumann indigo synthesis Hiyama coupling Hydration reaction Hydroamination Hydrodesulfurization Hydrogenolysis Hydrosilylation Hinsberg indole synthesis Hinsberg oxindole synthesis Hinsberg reaction Hinsberg separation Hinsberg sulfone synthesis Hirao coupling Hoch–Campbell ethylenimine synthesis Hock rearrangement Hofmann bromamide reaction Hofmann degradation, Exhaustive methylation Hofmann elimination Hofmann Isonitrile synthesis, Carbylamine reaction Hofmann product Hofmann rearrangement Hofmann–Löffler reaction, Löffler–Freytag reaction, Hofmann–Löffler–Freytag reaction Hofmann–Martius rearrangement Hofmann's rule Hofmann–Sand reaction Homo rearrangement of steroids Hooker reaction Horner–Wadsworth–Emmons reaction Hoesch reaction Hosomi–Sakurai reaction Houben–Fischer synthesis Hudlicky fluorination Huisgen cycloaddition Hunsdiecker reaction, Hunsdiecker–Borodin reaction Hurd-Mori 1,2,3-thiadiazole synthesis Hurtley reaction Hydroboration Hydrocarbon cracking Hydrohalogenation
Sources: en.wikipedia.org
== History == SR-17018 was patented in 2016 and first described in the scientific literature by Laura Bohn and colleagues at the Scripps Research Institute in Jupiter, Florida in 2017. The drug was encountered as a novel designer drug online by 2023. Analogues like brorphine and SR-14968 have also been encountered as novel designer drugs. Brorphine is said to not be popular among recreational users as it produces little euphoria but reportedly still has potential for severe respiratory depression. In 2024, discussion of SR-17018 on the social media website Reddit suddenly dramatically increased and the drug emerged as an informal treatment for opioid discontinuation and withdrawal. On July 1, 2026, the United States Drug Enforcement Administration (DEA) signed a letter of intent to temporarily place SR-17018 under Schedule I of the Controlled Substances Act. This will likely take effect on July 31, 2026. There has been opposition to the announcement, for instance by the Students for Sensible Drug Policy (SSDP).
The federation is set on five fundamental principles: sovereignty, citizenship, dignity of human beings, the social values of labor and freedom of enterprise, and political pluralism. The classic tripartite branches of government (executive, legislative and judicial under a checks and balances system) are formally established by the constitution. The executive and legislative are organized independently in all three spheres of government, while the judiciary is organized only at the federal and state and Federal District spheres. All members of the executive and legislative branches are directly elected. For most of its democratic history, Brazil has had a multi-party system, with proportional representation. Voting is compulsory for the literate between 18 and 70 years old and optional for illiterates and those between 16 and 18 or beyond 70. The country has around 30 registered political parties. Twenty political parties are represented in Congress. It is common for politicians to switch parties, and thus the proportion of congressional seats held by particular parties changes regularly.
[We] have to act according not only to the facts but to the ... evidence. I am sure you understand that these are very grave accusations." The European Ombudsman, Emily O'Reilly, was, however critical of the response of Von der Leyen and fellow politicians and institutions, highlighting the lack of progress shown by von der Leyen following her pledge that transparency would be a core part of her mandate when she became European Commission President. O'Reilly called for a body to be created with real investigatory and sanctions powers. The Belgian Prime Minister, Alexander De Croo, was also critical of the European institutions in his response, stating that "Belgian justice is doing what, at first sight, the European Parliament hasn't done." "The European Parliament has a lot of means to regulate itself. It turns out that this is largely a system of auto-control based on voluntary efforts, which has clearly not been sufficient." Annalena Baerbock, the German Minister for Foreign Affairs, highlighted that the scandal is leading to concerns from citizens and affects the credibility and legitimacy of the institutions of the European Union. On 15 December the European People's Party (EPP) reacted by declaring, "We need to discuss hypocrisy ... This is an S&D scandal." In an attempt to focus the scandal on the Progressive Alliance of Socialists and Democrats Group (S&D), rather than the European Parliament as a whole, they continued, "There has been a consistent effort to turn #Qatargate into an institutional issue alone. But this scandal is not an orphan. ... It has an address.
=== Flexural anatomy === Flexural anatomy is frequently described as a difficult area. It is simplified when each flexure is considered as being centered on a mesenteric contiguity. The ileocaecal flexure arises at the point where the ileum is continuous with the caecum around the ileocaecal mesenteric flexure. Similarly, the hepatic flexure is formed between the right mesocolon and transverse mesocolon at the mesenteric confluence. The colonic component of the hepatic flexure is draped around this mesenteric confluence. Furthermore, the splenic flexure is formed by the mesenteric confluence between the transverse and left mesocolon. The colonic component of the splenic flexure occurs lateral to the mesenteric confluence. At every flexure, a continuous peritoneal fold lies outside the colonic/mesocolic complex tethering this to the posterior abdominal wall.
Therefore, ketone bodies are a way to move energy from the liver to other cells. The liver does not have the critical enzyme, succinyl CoA transferase, to process ketone bodies, and therefore cannot undergo ketolysis. The result is that the liver only produces ketone bodies, but does not use a significant amount of them.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.